Last updated on October 2018

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

Brief description of study

The purpose of this study is to evaluate the efficacy of pimavanserin by comparing pimavanserin with placebo in preventing a relapse of psychotic symptoms in subjects with dementia-related psychosis and who were stabilized after 12 weeks of open label pimavanserin treatment.

Clinical Study Identifier: NCT03325556

Contact Investigators or Research Sites near you

Start Over

Scott Stubbe

Memory Enhancement Center of America, Inc.
Eatontown, NJ United States
  Connect »